These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 3679617)

  • 1. Factors affecting serum protein binding of phenytoin, diazepam and propranolol in acute renal diseases.
    Tiula E; Haapanen EJ; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1987 Sep; 25(9):469-75. PubMed ID: 3679617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases.
    Tiula E; Tallgren LG; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):545-52. PubMed ID: 3429058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum protein binding of phenytoin, diazepam and propranolol in age-related decrease in renal function.
    Tiula E; Elfving S
    Ann Clin Res; 1987; 19(3):163-9. PubMed ID: 3674731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of total drug concentration on the free fraction in uremic sera.
    Tiula E; Neuvonen PJ
    Ther Drug Monit; 1986; 8(1):27-31. PubMed ID: 3961893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin.
    Lai CM; Moore P; Quon CY
    Res Commun Mol Pathol Pharmacol; 1995 Apr; 88(1):51-62. PubMed ID: 7620838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum protein binding of diazepam and propranolol in the feto-maternal unit from early to late pregnancy.
    Krauer B; Nau H; Dayer P; Bischof P; Anner R
    Br J Obstet Gynaecol; 1986 Apr; 93(4):322-8. PubMed ID: 3964607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The protein binding of phenytoin, propranolol, diazepam, and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum.
    McNamara PJ; Blouin RA; Brazzell RK
    Pharm Res; 1988 May; 5(5):261-5. PubMed ID: 3149736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects.
    Benedek IH; Blouin RA; McNamara PJ
    Br J Clin Pharmacol; 1984 Dec; 18(6):941-6. PubMed ID: 6529534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter.
    Terao N; Shen DD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):369-75. PubMed ID: 6631719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum protein binding of sulfisoxazole and diazepam in patients with chronic obstructive pulmonary disease.
    Guerrero J; García-Morillas M; Gil-Extremera B; Erill S
    Int J Clin Pharmacol Ther Toxicol; 1987 May; 25(5):255-8. PubMed ID: 3596851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum protein binding of drugs is not altered in patients with severe chronic cardiac failure.
    Fichtl B; Meister W; Schmied R
    Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):241-4. PubMed ID: 6862728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma protein binding of salicylic acid, phenytoin, chlorpromazine, propranolol and pethidine using equilibrium dialysis and ultracentrifugation.
    Verbeeck RK; Cardinal JA
    Arzneimittelforschung; 1985; 35(6):903-6. PubMed ID: 4026915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of age and sex on the plasma binding of acidic and basic drugs.
    Verbeeck RK; Cardinal JA; Wallace SM
    Eur J Clin Pharmacol; 1984; 27(1):91-7. PubMed ID: 6489431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma protein binding of ethinyloestradiol: effect of disease and interaction with drugs.
    Pacifici GM; Viani A; Rizzo G; Carrai M
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):362-5. PubMed ID: 2777426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
    Joerger M; Huitema AD; Boogerd W; van der Sande JJ; Schellens JH; Beijnen JH
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):133-40. PubMed ID: 16918714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of smoking on serum protein composition and the protein binding of drugs.
    Benedek IH; Blouin RA; McNamara PJ
    J Pharm Pharmacol; 1984 Mar; 36(3):214-6. PubMed ID: 6144765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in drug free fraction during alcohol withdrawal.
    Sandor P; Naranjo CA; Khouw V; Sellers EM
    Br J Clin Pharmacol; 1983 Apr; 15(4):481-6. PubMed ID: 6849785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of three methods for predicting concentrations of free phenytoin.
    Beck DE; Farringer JA; Ravis WR; Robinson CA
    Clin Pharm; 1987 Nov; 6(11):888-94. PubMed ID: 3677566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of plasma free phenytoin measurement and factors influencing its protein binding.
    Iwamoto T; Kagawa Y; Naito Y; Kuzuhara S; Okuda M
    Biopharm Drug Dispos; 2006 Mar; 27(2):77-84. PubMed ID: 16308884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the drug-binding defect in plasma from rats with glycerol-induced acute renal failure.
    Bowmer CJ; Lindup WE
    J Pharmacol Exp Ther; 1979 Sep; 210(3):440-5. PubMed ID: 480193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.